Breast cancer

[1] Agus D, 2003, P AN M AM SOC CLIN, V22, P192

[2] Prospective identification of tumorigenic breast cancer cells[J]. Al-Hajj, M;Wicha, MS;Benito-Hernandez, A;Morrison, SJ;Clarke, MF. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003(07)

[3] Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[4] Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer[J]. Allen, LF;Eiseman, IA;Fry, DW;Lenehan, PF. SEMINARS IN ONCOLOGY, 2003(05)

[5] [Anonymous], 2004, Tobacco smoke and involuntary smoking

[6] [Anonymous], [No title captured]

[7] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer[J]. Ayers, M;Symmans, WF;Stec, J;Damokosh, AI;Clark, E;Hess, K;Lecocke, M;Metivier, J;Booser, D;Ibrahim, N;Valero, V;Royce, M;Arun, B;Whitman, G;Ross, J;Sneige, N;Hortobagyi, GN;Pusztai, L. JOURNAL OF CLINICAL ONCOLOGY, 2004(12)

[8] Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. Bardou, VJ;Arpino, G;Elledge, RM;Osborne, CK;Clark, GM. JOURNAL OF CLINICAL ONCOLOGY, 2003(10)

[9] Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients[J]. Barnes, DM;Harris, WH;Smith, P;Millis, RR;Rubens, RD. BRITISH JOURNAL OF CANCER, 1996(09)

[10] Dosimetric effects within target and organs at risk of interfractional patient mispositioning in left breast cancer radiotherapy[J]. Baroni, G;Garibaldi, C;Scabini, M;Riboldi, M;Catalano, G;Tosi, G;Orecchia, R;Pedotti, A. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004(03)

[1] Agus D, 2003, P AN M AM SOC CLIN, V22, P192

[2] Prospective identification of tumorigenic breast cancer cells[J]. Al-Hajj, M;Wicha, MS;Benito-Hernandez, A;Morrison, SJ;Clarke, MF. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003(07)

[3] Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[4] Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer[J]. Allen, LF;Eiseman, IA;Fry, DW;Lenehan, PF. SEMINARS IN ONCOLOGY, 2003(05)

[5] [Anonymous], 2004, Tobacco smoke and involuntary smoking

[6] [Anonymous], [No title captured]

[7] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer[J]. Ayers, M;Symmans, WF;Stec, J;Damokosh, AI;Clark, E;Hess, K;Lecocke, M;Metivier, J;Booser, D;Ibrahim, N;Valero, V;Royce, M;Arun, B;Whitman, G;Ross, J;Sneige, N;Hortobagyi, GN;Pusztai, L. JOURNAL OF CLINICAL ONCOLOGY, 2004(12)

[8] Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. Bardou, VJ;Arpino, G;Elledge, RM;Osborne, CK;Clark, GM. JOURNAL OF CLINICAL ONCOLOGY, 2003(10)

[9] Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients[J]. Barnes, DM;Harris, WH;Smith, P;Millis, RR;Rubens, RD. BRITISH JOURNAL OF CANCER, 1996(09)

[10] Dosimetric effects within target and organs at risk of interfractional patient mispositioning in left breast cancer radiotherapy[J]. Baroni, G;Garibaldi, C;Scabini, M;Riboldi, M;Catalano, G;Tosi, G;Orecchia, R;Pedotti, A. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004(03)